Stock Events

Stock Events

Ampio Pharmaceuticals 

0
48
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
0Revenue
-7.93MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow APH.STU. It's not an investment recommendation.
Tesla
7
TSLA
Apple
6
AAPL
Amazon
5
AMZN
Intel
4
INTC

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global pharmaceutical company that competes with Ampio in the development of therapies for inflammatory conditions, a key area for Ampio.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical segment, competes in developing drugs for similar conditions that Ampio targets, including pain management and inflammation.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie operates in the same therapeutic areas as Ampio, particularly in inflammation and immunology, making it a direct competitor.
Merck
MRK
Mkt Cap366B
Merck & Co. competes with Ampio in the pharmaceutical sector, focusing on innovative therapies, including treatments for inflammatory diseases.
AMGEN
AMGN
Mkt Cap233.78B
Amgen focuses on biologic medicines, including treatments for inflammatory diseases, directly competing with Ampio's product pipeline.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb offers a range of products that target inflammation and immune disorders, competing with Ampio's development focus.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is involved in the discovery, development, and commercialization of medicines in areas overlapping with Ampio's interests, including inflammatory diseases.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals specializes in developing drugs for inflammatory conditions and other immune-related diseases, making it a competitor to Ampio.
Novartis
NVS
Mkt Cap292.35B
Novartis is a global healthcare company that develops treatments for a wide range of diseases, including those related to inflammation, competing with Ampio's therapeutic focus.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on advanced therapies for serious diseases, including inflammatory conditions, positioning it as a competitor to Ampio in the biopharmaceutical sector.

About

Ampio Pharmaceuticals, Inc., headquartered in Englewood, Colorado, is a biopharmaceutical firm dedicated to advancing immunomodulatory therapeutics primarily for the management of osteoarthritis pain across the United States. Their developmental pipeline currently features several compounds: AP-013, an intra-articular injection, is undergoing Phase III clinical trials for knee osteoarthritis. Additionally, the company has multiple candidates addressing COVID-19: AP-017, an intravenous Ampion formulation, is in Phase II for adult COVID-19 patients who require supplemental oxygen; AP-019, an inhaled Ampion treatment, also in Phase II, targets adults experiencing respiratory distress from COVID-19; while AP-018, currently in Phase I, aims to treat individuals with persistent respiratory symptoms following COVID-19 infection.
Show more...
CEO
Michael A. Martino
Employees
6
Country
United States
ISIN
US03209T1097
WKN
000A3DV68

Listings

STU
DE
APH.STU
OTC Link
US
AMPE

0 Comments

Share your thoughts

FAQ

What is Ampio Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Ampio Pharmaceuticals stocks are traded under the ticker APH.STU.
What is Ampio Pharmaceuticals revenue for the last year?▼
Ampio Pharmaceuticals revenue for the last year amounts to 0 EUR.
What is Ampio Pharmaceuticals net income for the last year?▼
APH.STU net income for the last year is -7.93M EUR.
How many employees does Ampio Pharmaceuticals have?▼
As of September 06, 2026, the company has 6 employees.
In which sector is Ampio Pharmaceuticals located?▼
Ampio Pharmaceuticals operates in the Health & Wellness sector.
When did Ampio Pharmaceuticals complete a stock split?▼
The last stock split for Ampio Pharmaceuticals was on November 10, 2022 with a ratio of 1:15.
Where is Ampio Pharmaceuticals headquartered?▼
Ampio Pharmaceuticals is headquartered in Englewood, United States.